Form D · Biotechnology

HAWKHILL THERAPEUTICS Ltd

Dundee, Scotland, X0 · CIK 0002140690

Offering snapshot reported Sep 29, 2026 · SEC filing

Reported sold
$291K
Offering amount: $291K
Investors reported
1
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Apr 7, 2026
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$145K$291KJun 23, 2026: $192,569.00Jun 23, 2026Sep 29, 2026: $290,530.00Sep 29, 2026

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$192,569 → $290,530

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Sep 29, 2026Amendment$290,530$97,961vs Jun 23, 20261SEC filing
Jun 23, 2026Initial$192,569No comparison1SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-588182

Source: Form D, filed Sep 29, 2026. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Antoine Boulanger Director
Mary Canning Director
Francisca Peixoto Director
Timothy Jason Sparey Director
Christopher Andrew Woodland Director, Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
Life Sciences Innovation Hub 5 James Lindsay Place
Dundee, Scotland, X0, DD1 5JJ
Phone: 5555555555